The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study
Authors' conclusion
A single 60-mg dose of denosumab effectively reduces serum calcium levels in PHPT patients with moderate/severe hypercalcemia, at least maintaining efficacy for a median of nearly 3 weeks without serious adverse events.
Study context
- Population
- Primary hyperparathyroidism (PHPT) patients with moderate/severe hypercalcemia (corrected serum calcium [CSC] ≥ 3.0 mmol/L)CSC-matched
- Participants
- 29 vs 29
- Exposure
- Denosumab vs zoledronic acid
- Dmabn = 29
- ZAn = 29reference
- Outcome
- Change of CSC (ΔCa)
Methodological detailsCSC-matched
- CSC-matched
Main finding
As reported in the abstract
CSC, baseline to post-treatment
- Dmab: CSC 3.37 ± 0.37 to 2.64 ± 0.33 mmol/L
- P < .01
- ZA: CSC 3.41 ± 0.32 to 2.57 ± 0.23 mmol/L
- P < .01
Observational data: associations, not effects.
Secondary outcomes
Time to CR · shorter with ZA
P < 0.01
Duration of response · longer with Dmab
P = 0.02
| Outcome | Dmab | ZA |
|---|---|---|
| Response (CSC <3.0 mmol/L) | 82.8% | — not stated in the abstract |
| Complete response (CSC <2.7 mmol/L) | 72.4% | — not stated in the abstract |
— not stated in the abstract
Response (CSC <3.0 mmol/L)
- Comparable to ZA
Complete response (CSC <2.7 mmol/L)
- Comparable to ZA
Safety
| Outcome | Dmab | ZA |
|---|---|---|
| Hypocalcemia | 6.9% | 0 events |
- Hypocalcemia: both Dmab cases with CKD stage 3b
Original publication
The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study. J Clin Endocrinol Metab. Published 3 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →